Observing the progression of diabetic retinopathy in patients with type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to track the development of non-perfusion areas in the retina of type 2 diabetes patients aged 18-75. Participants will undergo follow-up examinations over a period of 5 years to assess the formation and expansion of these areas, which may indicate the progression of diabetic retinopathy. The study will evaluate whether posterior retinal non-perfusion occurs earlier than peripheral non-perfusion and if the rate of expansion serves as a risk factor for disease progression. The study includes detailed assessments of medical history, medications, and eye health.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Patients with type 2 diabetes aged 18-75 years
* Can cooperate with the inspection and sign the informed consent
* There are no other eye diseases that cause retinal neovascularization
* There is no known substantial media haze that would hinder fundus image acquisition
* No history of fundus laser treatment or no possibility of laser treatment expected within six months
* No previous history of intravitreal drug injection, and no intravitreal drug injection is expected in the next 6 months
* Macular edema without diabetes (Zeiss OCT women \< 290µm, male \< 305µm; OCT female in Heidelberg is \< 305µm, and for males \< 320µm)
* In the field of visual field of clinical mydriasis and Optos photo 7 field of view, DR Lesions were less severe than NPDR
* No history of eye surgery

Exclusion criteria:

* Patients with kidney failure.
* History of systemic anti-VEGF therapy within the last month.
* Follow-up is expected to be difficult or patients from other provinces have traction retinal detachment;
* The patient has a history of allergy

Where it's running

• Sichuan Academy of Medical Science Sichuan Provincial Hosptial
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Jie Li, doctor
• Email: lijieyk@med.uestc.edu.cn
• Phone: +86 13908094675

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy

  This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.

  Recruiting Phase 4 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07843849

• Automated detection of diabetic retinopathy lesions in fundus photos

  This study tests a smart imaging system within the DDART device to see if it can reliably spot diabetic retinopathy lesions in color fundus photographs.

  Recruiting Democritus University of Thrace · Alexandroupoli · NCT07758582

• Retinal microvascular changes in diabetic retinopathy measured with OCTA

  This observational study tests how retinal blood vessel patterns seen on OCTA relate to vision and blood sugar control in adults with diabetic retinopathy.

  Recruiting Sohag University · Sohag · NCT07747428

• MK-8748 vs. aflibercept for diabetic macular edema

  This trial tests whether the investigational medicine MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in adults with diabetes.

  Recruiting at 20 sites Phase 3 Merck Sharp & Dohme LLC · Long Beach, California and 19 other locations · NCT07705607

• MK-8748 vs aflibercept for diabetic macular edema

  This trial tests whether MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in people with diabetes.

  Recruiting at 35 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 34 other locations · NCT07705555

• Surabgene Lomparvovec in the Suprachoroidal Space for Diabetic Retinopathy

  This study tests a one-time gene therapy called surabgene lomparvovec to see if it can help adults with non-proliferative diabetic retinopathy avoid vision-threatening events.

  Recruiting at 40 sites Phase 2/3 AbbVie · Mesa, Arizona and 39 other locations · NCT07592273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.